Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.56 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745654 | 0.90 | BRD4 (0.55) | BRD4CAMKK2HTR6 | |
| SCHEMBL1487576 | 0.88 | HTR6 (0.45) | BRD4CAMKK2PTGS2FYNSCN9A | |
| SCHEMBL8325104 | 0.88 | BRD4 (0.60) | BRD4HTR6 | |
| SCHEMBL13746241 | 0.87 | BRD4 (0.54) | BRD4HTR6 | |
| SCHEMBL13745801 | 0.84 | CAMKK2 (0.42) | BRD4CAMKK2PTGS2FYNIGF1R | |
| SCHEMBL8324896 | 0.83 | BRD4 (0.60) | BRD4SCN9APTPN11HTR6 | |
| SCHEMBL13745799 | 0.82 | BRD4 (0.41) | BRD4CAMKK2PTGS2FYNPTPN11 | |
| SCHEMBL1799967 | 0.82 | BRD4 (0.67) | BRD4PTPN11HTR6 | |
| SCHEMBL14031013 | 0.82 | BRD4 (0.41) | BRD4CAMKK2PTGS2FYNSCN9A | |
| SCHEMBL13746458 | 0.82 | BRD4 (0.41) | BRD4CAMKK2PTGS2FYNPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295433-A2 | JNK inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060270646-A1 | Jnk inhibitors | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270646-A1 | Jnk inhibitors | MAPKAPK2, MAPK1, MAPKAPK3 | BRD4 1384/4885CAMKK2 89/4885PTGS2 701/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | BRD4 1339/4885CAMKK2 94/4885PTGS2 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.